This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Industry Insists Australian Clinical Trials Are Internationally Cost Competitive Contrary To 2012 Report

 

SYDNEY, May 20, 2013 /PRNewswire/ -- Industry claims that a report of Australian clinical trial costs is flawed. The report ( https://www.kpmg.com/Global/en/IssuesAndInsights/ArticlesPublications/Documents/competitive-alternatives-special-report.pdf) on the global competitiveness of 14 countries came out this time last year, ranking Australia as the second most expensive country to run clinical trials, subsequent press accepted the report and said what a shame it was that Australia was so costly compared with other countries...

In the spirit of promoting Australia's advantages, timely for International Clinical Trials Day ( 20th May 2013), Australian R&D industry representatives are now making noise in response to the report. The report rankings were based on areas such as labour costs, transport, facility lease costs and utilities such as electricity. Exact data sources are unclear.

"The report should be judged in context with the data it used" says Luke Edington, Clinical Project Management ( http://www.datapharmaustralia.com/about-us/our-leaders) at Datapharm Australia. "Broad economic indicators are not sufficient to draw solid conclusions on clinical trial management costs, and it is unfair to rank a country's R&D costs on these factors alone. It seems no consideration was given to R&D Tax incentive(s), regulatory environments, time to first patient, patient population access, Investigator fees & laboratory costs, recruitment rates, insurance, ethics fees, CRO operating costs and other quality dynamics." says Mr Edington

If you consider that the Australian R&D tax incentive was not included in this report, currently being up to 45%, this alone would have placed Australia competitively with Russia. "Foreign entities can claim R&D Tax incentives ( http://www.swansonreed.com.au/product/45-rebate-for-australian-rd-costs/) through their Australian subsidiaries at 45 cents in the dollar, that means $450,000 for $1,000,000 foreign spend in Australia", says Adam Rogers, R&D Tax specialist at Swanson & Reed.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs